Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study.

delayed oophorectomy early menopause high risk of breast and ovarian cancer ovarian cancer prevention radical fimbriectomy risk-reducing surgery

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
10 02 2023
Historique:
received: 20 01 2023
revised: 07 02 2023
accepted: 07 02 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 26 2 2023
Statut: epublish

Résumé

Risk-reducing salpingo-oophorectomy is the gold standard for the prophylaxis of ovarian cancer in high-risk women. Due to significant adverse effects, 20-30% of women delay or refuse early oophorectomy. This prospective pilot study (NCT01608074) aimed to assess the efficacy of radical fimbriectomy followed by a delayed oophorectomy in preventing ovarian and pelvic invasive cancer (the primary endpoint) and to evaluate the safety of both procedures. The key eligibility criteria were pre-menopausal women ≥35 years with a high risk of ovarian cancer who refused a risk-reducing salpingo-oophorectomy. All the surgical specimens were subjected to the SEE-FIM protocol. From January 2012 to October 2014, 121 patients underwent RF, with 51 in an ambulatory setting. Occult neoplasia was found in two cases, with one tubal high-grade serous ovarian carcinoma. Two patients experienced grade 1 intraoperative complications. No early or delayed grade ≥3 post-operative complications occurred. After 7.3 years of median follow-up, no cases of pelvic invasive cancer have been noted. Three of the fifty-two patients developed de novo breast cancer. One BRCA1-mutated woman delivered twins safely. Twenty-five patients underwent menopause, including fifteen who had received chemotherapy for breast cancer, and twenty-three underwent menopause before the delayed oophorectomy, while two did not undergo a delayed oophorectomy at all. Overall, 46 women underwent a delayed oophorectomy. No abnormalities were found in any delayed oophorectomy specimens. Radical fimbriectomy followed by delayed oophorectomy appears to be a safe and well-tolerated risk-reducing approach, which avoids early menopause for patients with a high risk of breast and ovarian cancer.

Identifiants

pubmed: 36831483
pii: cancers15041141
doi: 10.3390/cancers15041141
pmc: PMC9954021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : French National Cancer Institute
ID : PHRC 2011-06

Références

JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
Int J Gynecol Pathol. 2011 Jan;30(1):12-21
pubmed: 21131839
Am J Obstet Gynecol. 2011 Jan;204(1):19.e1-6
pubmed: 20619389
Clin Cancer Res. 2017 Jul 15;23(14):3628-3637
pubmed: 28143870
J Clin Oncol. 2007 Apr 10;25(11):1329-33
pubmed: 17416853
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Nat Rev Cancer. 2010 Nov;10(11):803-8
pubmed: 20944665
Int J Gynecol Pathol. 2011 Jan;30(1):4-11
pubmed: 21131840
Am J Surg Pathol. 2011 Dec;35(12):1766-75
pubmed: 21989347
Maturitas. 2011 Nov;70(3):261-5
pubmed: 21893388
J Natl Cancer Inst. 2015 Aug 27;107(11):
pubmed: 26315354
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
Hum Reprod. 2011 Dec;26(12):3494-5; author reply 3495
pubmed: 22016419
Am J Surg Pathol. 2007 Feb;31(2):161-9
pubmed: 17255760
J Pathol. 2001 Nov;195(4):451-6
pubmed: 11745677
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Pathol Transl Med. 2018 Jan;52(1):21-27
pubmed: 27539290
Hum Mutat. 2012 Apr;33(4):690-702
pubmed: 22253144
Cochrane Database Syst Rev. 2018 Aug 24;8:CD012464
pubmed: 30141832
Br J Cancer. 2019 Jul;121(1):15-21
pubmed: 30971774
Ann Oncol. 2013 Dec;24 Suppl 10:x16-21
pubmed: 24265397
Int J Gynecol Pathol. 2015 Mar;34(2):112-20
pubmed: 25675178
Breast Cancer Res Treat. 2019 Oct;177(3):723-733
pubmed: 31302855
BJOG. 2017 May;124(6):872-878
pubmed: 28218502
Obstet Gynecol Sci. 2019 Nov;62(6):382-390
pubmed: 31777733
JAMA Oncol. 2021 Aug 01;7(8):1203-1212
pubmed: 34081085
Nat Commun. 2019 Nov 26;10(1):5367
pubmed: 31772167
J Clin Endocrinol Metab. 2017 Oct 1;102(10):3839-3847
pubmed: 28938488
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Int J Gynecol Cancer. 2021 Feb;31(2):286-291
pubmed: 32907814
Cancers (Basel). 2018 Nov 28;10(12):
pubmed: 30486509
J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):837-842
pubmed: 28479170
J Cancer Res Ther. 2018 Apr-Jun;14(3):543-548
pubmed: 29893313
Maturitas. 2010 Jul;66(3):310-4
pubmed: 20409655
Cancer Cell. 2013 Dec 9;24(6):751-65
pubmed: 24332043
Curr Oncol. 2017 Dec;24(6):e494-e502
pubmed: 29270058
Gynecol Oncol. 2017 Jun;145(3):595-602
pubmed: 28237618
Med Decis Making. 2009 May-Jun;29(3):343-50
pubmed: 19073996
Obstet Gynecol. 2009 May;113(5):1027-1037
pubmed: 19384117
Cancers (Basel). 2018 Nov 12;10(11):
pubmed: 30424539
JNCI Cancer Spectr. 2018 Dec 14;2(4):pky061
pubmed: 31360879
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47
pubmed: 22144499
Adv Anat Pathol. 2006 Jan;13(1):1-7
pubmed: 16462151
Gynecol Oncol. 2009 Jun;113(3):391-6
pubmed: 19237187
Gynecol Oncol. 2011 Jun 1;121(3):472-6
pubmed: 21411127
Gynecol Oncol. 2019 Jan;152(1):145-150
pubmed: 30414741

Auteurs

Eric Leblanc (E)

Department of Gynecologic Oncology, Centre Oscar Lambret, 3 rue Frédéric Combemale, 59020 Lille, France.
INSERM U1192, Université de Lille, 59000 Lille, France.

Fabrice Narducci (F)

Department of Gynecologic Oncology, Centre Oscar Lambret, 3 rue Frédéric Combemale, 59020 Lille, France.
INSERM U1192, Université de Lille, 59000 Lille, France.

Gwenaël Ferron (G)

Centre Claudius Regaud, 31300 Toulouse, France.

Audrey Mailliez (A)

Medical Oncology Department, Centre Oscar Lambret, 59020 Lille, France.

Jean-Yves Charvolin (JY)

Clinique du Bois, 59000 Lille, France.

El Hajj Houssein (EH)

Department of Gynecologic Oncology, Centre Oscar Lambret, 3 rue Frédéric Combemale, 59020 Lille, France.

Frédéric Guyon (F)

Institut Jean-Alban Bergonié, 33076 Bordeaux, France.

Virginie Fourchotte (V)

Institut Curie, 75248 Paris, France.

Eric Lambaudie (E)

Institut Paoli-Calmettes, 13009 Marseille, France.

Agathe Crouzet (A)

Centre Henri Becquerel, 76038 Rouen, France.

Yves Fouche (Y)

Centre Antoine Lacassagne, 06100 Nice, France.

Sébastien Gouy (S)

Institut Gustave Roussy, 94805 Villejuif, France.

Pierre Collinet (P)

Hôpital Jeanne de Flandre, CHRU, 59000 Lille, France.

Frédéric Caquant (F)

Hôpital Privé de Villeneuve d'Ascq, 59650 Villeneuve-d'Ascq, France.

Christophe Pomel (C)

Centre Jean Perrin, 63011 Clermont-Ferrand, France.

François Golfier (F)

Hospices Civils de Lyon, 69002 Lyon, France.

Véronique Vaini-Cowen (V)

Polyclinique du Parc Rambot, 13100 Aix en Provence, France.

Isabelle Fournier (I)

INSERM U1192, Université de Lille, 59000 Lille, France.

Michel Salzet (M)

INSERM U1192, Université de Lille, 59000 Lille, France.

Emmanuelle Tresch (E)

Biostatistics Unit, DRCI, Centre Oscar Lambret, 59020 Lille, France.

Alicia Probst (A)

Sponsor Unit, DRCI, Centre Oscar Lambret, 59020 Lille, France.

Anne-Sophie Lemaire (AS)

Pathology Department, Centre Oscar Lambret, 59020 Lille, France.

Marie-Cécile Le Deley (ML)

Sponsor Unit, DRCI, Centre Oscar Lambret, 59020 Lille, France.
Centre de Recherche en Epidémiologie et Santé des Populations, INSERM, Paris-Sud, Paris-Saclay University, 94800 Villejuif, France.

Delphine Hudry (D)

Department of Gynecologic Oncology, Centre Oscar Lambret, 3 rue Frédéric Combemale, 59020 Lille, France.
INSERM U1192, Université de Lille, 59000 Lille, France.

Classifications MeSH